Top

Current Neurology and Neuroscience Reports

Published in:

01-06-2016 | Movement Disorders (SH Fox, Section Editor)

Neurological Disorders Associated with Striatal Lesions: Classification and Diagnostic Approach

Authors: Davide Tonduti, Luisa Chiapparini, Isabella Moroni, Anna Ardissone, Giovanna Zorzi, Federica Zibordi, Sergio Raspante, Celeste Panteghini, Barbara Garavaglia, Nardo Nardocci

Published in: Current Neurology and Neuroscience Reports | Issue 6/2016

Abstract

Neostriatal abnormalities can be observed in a very large number of neurological conditions clinically dominated by the presence of movement disorders. The neuroradiological picture in some cases has been described as “bilateral striatal necrosis” (BSN). BSN represents a condition histo-pathologically defined by the involvement of the neostriata and characterized by initial swelling of putamina and caudates followed by degeneration and cellular necrosis. After the first description in 1975, numerous acquired and hereditary conditions have been associated with the presence of BSN. At the same time, a large number of disorders involving neostriata have been described as BSN, in some cases irrespective of the presence of signs of cavitation on MRI. As a consequence, the etiological spectrum and the nosographic boundaries of the syndrome have progressively become less clear. In this study, we review the clinical and radiological features of the conditions associated with MRI evidence of bilateral striatal lesions. Based on MRI findings, we have distinguished two groups of disorders: BSN and other neostriatal lesions (SL). This distinction is extremely helpful in narrowing the differential diagnosis to a small group of known conditions. The clinical picture and complementary exams will finally lead to the diagnosis. We provide an update on the etiological spectrum of BSN and propose a diagnostic flowchart for clinicians.

Roig M, Calopa M, Rovira A, Macaya A, Riudor E, Losada M. Bilateral striatal lesions in childhood. Pediatr Neurol. 1993;9:349–58.PubMedCrossRef

Friede R. Developmental neuropathology. 2nd ed. Berlin Heidelberg New York London Paris Tokyo: Springer-Velag; 1989.CrossRef

Livingston JH, Lin JP, Dale RC, Gill D, Brogan P, Munnich A, et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet. 2014;51:76–82.PubMedCrossRef

Dale, R.C., and Brilot, F. (2012). Autoimmune basal ganglia disorders. J Child Neurol.

Goutières F, Aicardi J. Acute neurological dysfunction associated with destructive lesions of the basal ganglia in children. Ann Neurol. 1982;12:328–32.PubMedCrossRef

Zambrino CA, Zorzi G, Lanzi G, Uggetti C, Egitto MG. Bilateral striatal necrosis associated with Mycoplasma pneumoniae infection in an adolescent: clinical and neuroradiologic follow up. Mov Disord. 2000;15:1023–6.PubMedCrossRef

van Buiren M, Uhl M. Images in clinical medicine. Bilateral striatal necrosis associated with Mycoplasma pneumoniae infection. N Engl J Med. 2003;348:720.PubMedCrossRef

Termine C, Uggetti C, Veggiotti P, Balottin U, Rossi G, Egitto MG, et al. Long-term follow-up of an adolescent who had bilateral striatal necrosis secondary to Mycoplasma pneumoniae infection. Brain Dev. 2005;27:62–5.PubMedCrossRef

Sasaki M, Matsuda H, Omura I, Sugai K, Hashimoto T. Transient seizure disappearance due to bilateral striatal necrosis in a patient with intractable epilepsy. Brain Dev. 2000;22:50–5.PubMedCrossRef

10.

Larsen PD, Crisp D. Acute bilateral striatal necrosis associated with Mycoplasma pneumoniae infection. Pediatr Infect Dis J. 1996;15:1124–6.PubMedCrossRef

11.

Green C, Riley DE. Treatment of dystonia in striatal necrosis caused by Mycoplasma pneumoniae. Pediatr Neurol. 2002;26:318–20.PubMedCrossRef

12.

Coon EA, Patterson MC. Teaching neuroimages: call it as you see it: evolution of bilateral striatal necrosis. Neurology. 2012;78:e123.PubMedCrossRef

13.

Brandel JP, Vidailhet M, Noseda G, Harpey JP, Agid Y. Mycoplasma pneumoniae postinfectious encephalomyelitis with bilateral striatal necrosis. Mov Disord. 1996;11:333–6.PubMedCrossRef

14.

Dale RC, Church AJ, Benton S, Surtees RA, Lees A, Thompson EJ, et al. Post-streptococcal autoimmune dystonia with isolated bilateral striatal necrosis. Dev Med Child Neurol. 2002;44:485–9.PubMedCrossRef

15.

Karagulle Kendi AT, Krenzel C, Ott FW, Brace JR, Norberg SK, Kieffer SA. Poststreptococcal dystonia with bilateral striatal enlargement: MR imaging and spectroscopic findings. AJNR Am J Neuroradiol. 2008;29:1276–8.PubMedCrossRef

16.

Dale RC, Church AJ, Cardoso F, Goddard E, Cox TC, Chong WK, et al. Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol. 2001;50:588–95.PubMedCrossRef

17.

Voudris KA, Skardoutsou A, Hasiotou M, Theodoropoulos B, Vagiakou EA. Long-term findings on brain magnetic resonance imaging in acute encephalopathy with bilateral striatal necrosis associated with measles. J Child Neurol. 2002;17:776–7.PubMedCrossRef

18.

Colamaria V, Plouin P, Dulac O, Cesaro G, Dalla Bernardina B. Kojewnikow’s epilepsia partialis continua: two cases associated with striatal necrosis. Neurophysiol Clin. 1988;18:525–30.PubMedCrossRef

19.

Cambonie G, Houdon L, Rivier F, Bongrand AF, Echenne B. Infantile bilateral striatal necrosis following measles. Brain Dev. 2000;22:221–3.PubMedCrossRef

20.

Murakami A, Morimoto M, Adachi S, Ishimaru Y, Sugimoto T. Infantile bilateral striatal necrosis associated with human herpes virus-6 (HHV-6) infection. Brain Dev. 2005;27:527–30.PubMedCrossRef

21.

Mordekar S, Jaspan T, Sharrard M, Morton R, Whitehouse WP. Acute bilateral striatal necrosis with rotavirus gastroenteritis and inborn metabolic predisposition. Dev Med Child Neurol. 2005;47:415–8.PubMedCrossRef

22.

Yamamoto K, Chiba HO, Ishitobi M, Nakagawa H, Ogawa T, Ishii K. Acute encephalopathy with bilateral striatal necrosis: favourable response to corticosteroid therapy. Eur J Paediatr Neurol. 1997;1:41–5.PubMedCrossRef

23.•

Tabarki B, Al-Shafi S, Al-Shahwan S, Azmat Z, Al-Hashem A, Al-Adwani N, et al. Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology. 2013;80:261–7. Neurology 80, 261–267. Tabarki et al. review the clinical and radiological features of 10 new and 14 published SLC19A3 mutated patients. They underline the importance to consider this disorder in case of unexplained encephalopathy with typical neuroimaging features because a therapeutic trial can be lifesaving. They recommend that the medical community open the dialog to consider formally discontinuing the nosology “biotin basal ganglia disease” and to adopt the use of the term “biotin-thiamine responsive basal ganglia disease associated with SLC19A3 mutation.”.PubMedCrossRef

24.

Carrozzo R, Dionisi-Vici C, Steuerwald U, Lucioli S, Deodato F, Di Giandomenico S, et al. SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain. 2007;130:862–74.PubMedCrossRef

25.

Pigeon N, Campeau PM, Cyr D, Lemieux B, Clarke JT. Clinical heterogeneity in ethylmalonic encephalopathy. J Child Neurol. 2009;24:991–6.PubMedCrossRef

26.

Valayannopoulos V, Haudry C, Serre V, Barth M, Boddaert N, Arnoux JB, et al. New SUCLG1 patients expanding the phenotypic spectrum of this rare cause of mild methylmalonic aciduria. Mitochondrion. 2010;10:335–41.PubMedCrossRef

27.

Heringer J, Boy SP, Ensenauer R, Assmann B, Zschocke J, Harting I, et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol. 2010;68:743–52.PubMedCrossRef

28.

Orcesi S, Gorni K, Termine C, Uggetti C, Veggiotti P, Carrara F, et al. Bilateral putaminal necrosis associated with the mitochondrial DNA A8344G myoclonus epilepsy with ragged red fibers (MERRF) mutation: an infantile case. J Child Neurol. 2006;21:79–82.PubMedCrossRef

29.

Campos Y, Martin MA, Rubio JC, Gutierrez del Olmo MC, Cabello A, Arenas J. Bilateral striatal necrosis and MELAS associated with a new T3308C mutation in the mitochondrial ND1 gene. Biochem Biophys Res Commun. 1997;238:323–5.PubMedCrossRef

30.

De Meirleir L, Seneca S, Lissens W, Schoentjes E, Desprechins B. Bilateral striatal necrosis with a novel point mutation in the mitochondrial ATPase 6 gene. Pediatr Neurol. 1995;13:242–6.PubMedCrossRef

31.

Thyagarajan D, Shanske S, Vazquez-Memije M, De Vivo D, DiMauro S. A novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis. Ann Neurol. 1995;38:468–72.PubMedCrossRef

32.

Solano A, Roig M, Vives-Bauza C, Hernandez-Pena J, Garcia-Arumi E, Playan A, et al. Bilateral striatal necrosis associated with a novel mutation in the mitochondrial ND6 gene. Ann Neurol. 2003;54:527–30.PubMedCrossRef

33.

Aniello MS, Martino D, Petruzzella V, Eleopra R, Mancuso M, Dell'Aglio R, et al. Bilateral striatal necrosis, dystonia and multiple mitochondrial DNA deletions: case study and effect of deep brain stimulation. Mov Disord. 2008;23:114–8.PubMedCrossRef

34.

Barel O, Shorer Z, Flusser H, Ofir R, Narkis G, Finer G, et al. Mitochondrial complex III deficiency associated with a homozygous mutation in UQCRQ. Am J Hum Genet. 2008;82:1211–6.PubMedPubMedCentralCrossRef

35.

Debray FG, Seneca S, Gonce M, Vancampenhaut K, Bianchi E, Boemer F, et al. Mitochondrial encephalomyopathy with cytochrome c oxidase deficiency caused by a novel mutation in the MTCO1 gene. Mitochondrion. 2014;17:101–5.PubMedCrossRef

36.

Ghezzi D, Sevrioukova I, Invernizzi F, Lamperti C, Mora M, D'Adamo P, et al. Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor. Am J Hum Genet. 2010;86:639–49.PubMedPubMedCentralCrossRef

37.

Lebre AS, Rio M, Faivre d'Arcier L, Vernerey D, Landrieu P, Slama A, et al. A common pattern of brain MRI imaging in mitochondrial diseases with complex I deficiency. J Med Genet. 2011;48:16–23.PubMedCrossRef

38.

Uziel G, Ghezzi D, Zeviani M. Infantile mitochondrial encephalopathy. Semin Fetal Neonatal Med. 2011;16:205–15.PubMedCrossRef

39.

Baertling F, Rodenburg RJ, Schaper J, Smeitink JA, Koopman WJ, Mayatepek E, et al. A guide to diagnosis and treatment of Leigh syndrome. J Neurol Neurosurg Psychiatry. 2014;85:257–65.PubMedCrossRef

40.

Harting I, Neumaier-Probst E, Seitz A, Maier EM, Assmann B, Baric I, et al. Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I. Brain. 2009;132:1764–82.PubMedCrossRef

41.

Martínez Bermejo A, Arcas J, Roche MC, López-Martín V, Royo A, Merinero B, et al. Bilateral hypodensity of the basal ganglia. Clinico-evolutionary correlation in children. Rev Neurol. 2001;33:101–11.PubMed

42.

Sen A, Pillay RS. Striatal necrosis in type 1 glutaric aciduria: different stages in two siblings. J Pediatr Neurosci. 2011;6:146–8.PubMedPubMedCentral

43.

Strauss KA, Lazovic J, Wintermark M, Morton DH. Multimodal imaging of striatal degeneration in Amish patients with glutaryl-CoA dehydrogenase deficiency. Brain. 2007;130:1905–20.PubMedCrossRef

44.

Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130.PubMedPubMedCentralCrossRef

45.

Nizon M, Ottolenghi C, Valayannopoulos V, Arnoux JB, Barbier V, Habarou F, et al. Long-term neurological outcome of a cohort of 80 patients with classical organic acidurias. Orphanet J Rare Dis. 2013;8:148.PubMedPubMedCentralCrossRef

46.

Nyhan WL, Bay C, Beyer EW, Mazi M. Neurologic nonmetabolic presentation of propionic acidemia. Arch Neurol. 1999;56:1143–7.PubMedCrossRef

47.

Johnson JA, Le KL, Palacios E. Propionic acidemia: case report and review of neurologic sequelae. Pediatr Neurol. 2009;40:317–20.PubMedCrossRef

48.

Wortmann SB, De Brouwer APM, Wevers RA, Morava E. MEGDEL syndrome. 1993.

49.

Saudubray JM, Sedel F, Walter JH. Clinical approach to treatable inborn metabolic diseases: an introduction. J Inherit Metab Dis. 2006;29:261–74.PubMedCrossRef

50.

Ozand PT, Gascon GG, Al Essa M, Joshi S, Al Jishi E, Bakheet S, et al. Biotin-responsive basal ganglia disease: a novel entity. Brain. 1998;121(Pt 7):1267–79.PubMedCrossRef

51.

Debs R, Depienne C, Rastetter A, Bellanger A, Degos B, Galanaud D, et al. Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations. Arch Neurol. 2010;67:126–30.PubMedCrossRef

52.

Haack TB, Klee D, Strom TM, Mayatepek E, Meitinger T, Prokisch H, et al. Infantile Leigh-like syndrome caused by SLC19A3 mutations is a treatable disease. Brain. 2014;137:e295.PubMedCrossRef

53.

Yamada K, Miura K, Hara K, Suzuki M, Nakanishi K, Kumagai T, et al. A wide spectrum of clinical and brain MRI findings in patients with SLC19A3 mutations. BMC Med Genet. 2010;11:171.PubMedPubMedCentralCrossRef

54.

Alfadhel M, Almuntashri M, Jadah RH, Bashiri FA, Al Rifai MT, Al Shalaan H, et al. Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet J Rare Dis. 2013;8:83.PubMedPubMedCentralCrossRef

55.

Kassem H, Wafaie A, Alsuhibani S, Farid T. Biotin-responsive basal ganglia disease: neuroimaging features before and after treatment. AJNR Am J Neuroradiol. 2014;35:1990–5.PubMedCrossRef

56.

Zeng WQ, Al-Yamani E, Acierno Jr JS, Slaugenhaupt S, Gillis T, MacDonald ME, et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet. 2005;77:16–26.PubMedPubMedCentralCrossRef

57.

Zhao R, Goldman ID. Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol Aspects Med. 2013;34:373–85.PubMedCrossRef

58.

Vlasova TI, Stratton SL, Wells AM, Mock NI, Mock DM. Biotin deficiency reduces expression of SLC19A3, a potential biotin transporter, in leukocytes from human blood. J Nutr. 2005;135:42–7.PubMedPubMedCentral

59.

Kevelam SH, Bugiani M, Salomons GS, Feigenbaum A, Blaser S, Prasad C, et al. Exome sequencing reveals mutated SLC19A3 in patients with an early-infantile, lethal encephalopathy. Brain. 2013;136:1534–43.PubMedCrossRef

60.

Mayr JA, Freisinger P, Schlachter K, Rolinski B, Zimmermann FA, Scheffner T, et al. Thiamine pyrophosphokinase deficiency in encephalopathic children with defects in the pyruvate oxidation pathway. Am J Hum Genet. 2011;89:806–12.PubMedPubMedCentralCrossRef

61.

Rosenberg MJ, Agarwala R, Bouffard G, Davis J, Fiermonte G, Hilliard MS, et al. Mutant deoxynucleotide carrier is associated with congenital microcephaly. Nat Genet. 2002;32:175–9.PubMedCrossRef

62.

Spiegel R, Shaag A, Edvardson S, Mandel H, Stepensky P, Shalev SA, et al. SLC25A19 mutation as a cause of neuropathy and bilateral striatal necrosis. Ann Neurol. 2009;66:419–24.PubMedCrossRef

63.

Basel-Vanagaite L, Muncher L, Straussberg R, Pasmanik-Chor M, Yahav M, Rainshtein L, et al. Mutated nup62 causes autosomal recessive infantile bilateral striatal necrosis. Ann Neurol. 2006;60:214–22.PubMedCrossRef

64.

Straussberg R, Shorer Z, Weitz R, Basel L, Kornreich L, Corie CI, et al. Familial infantile bilateral striatal necrosis: clinical features and response to biotin treatment. Neurology. 2002;59:983–9.PubMedCrossRef

65.

Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012;135:3453–68.PubMedCrossRef

66.

Tzoulis C, Vedeler C, Haugen M, Storstein A, Tran GT, Gjerde IO, et al. Progressive striatal necrosis associated with anti-NMDA receptor antibodies. BMC Neurol. 2013;13:55.PubMedPubMedCentralCrossRef

67.

Chiapparini L, Granata T, Farina L, Ciceri E, Erbetta A, Ragona F, et al. Diagnostic imaging in 13 cases of Rasmussen’s encephalitis: can early MRI suggest the diagnosis? Neuroradiology. 2003;45:171–83.PubMed

68.••

Bekiesinska-Figatowska M, Mierzewska H, Jurkiewicz E. Basal ganglia lesions in children and adults. Eur J Radiol. 2013;82:837–49. Bekiesinska-Figatowska et al. make a review about basal ganglia lesions. MRI pattern recognition not alone but together with the knowledge of age and circumstances of onset and clinical course of the disease is a powerful tool of differential diagnosis. PubMedCrossRef

69.

Gataullina S, De Lonlay P, Dellatolas G, Valayannapoulos V, Napuri S, Damaj L, et al. Topography of brain damage in metabolic hypoglycaemia is determined by age at which hypoglycaemia occurred. Dev Med Child Neurol. 2013;55:162–6.PubMedCrossRef

70.

Kwon OD, Kim HK. Parkinsonism as late sequela of organophosphate intoxication. J Emerg Trauma Shock. 2014;7:124–5.PubMedPubMedCentralCrossRef

71.

Blanco M, Casado R, Vazquez F, Pumar JM. CT and MR imaging findings in methanol intoxication. AJNR Am J Neuroradiol. 2006;27:452–4.PubMed

72.

Gaul HP, Wallace CJ, Auer RN, Fong TC. MR findings in methanol intoxication. AJNR Am J Neuroradiol. 1995;16:1783–6.PubMed

73.

Glazer M, Dross P. Necrosis of the putamen caused by methanol intoxication: MR findings. AJR Am J Roentgenol. 1993;160:1105–6.PubMedCrossRef

74.

Hopkins RO, Fearing MA, Weaver LK, Foley JF. Basal ganglia lesions following carbon monoxide poisoning. Brain Inj. 2006;20:273–81.PubMedCrossRef

75.

Ozelame RV, Shroff M, Wood B, Bouffet E, Bartels U, Drake JM, et al. Basal ganglia germinoma in children with associated ipsilateral cerebral and brain stem hemiatrophy. Pediatr Radiol. 2006;36:325–30.PubMedCrossRef

76.

Bekiesinska-Figatowska M, Kuczynska-Zardzewialy A, Pomianowska B, Kajdana K, Szpak GM, Iwanowska B, et al. The value of magnetic resonance imaging in the early diagnosis of Creutzfeldt-Jakob disease—own experience. Pol J Radiol. 2012;77:63–7.PubMedPubMedCentralCrossRef

77.

Barkovich, A., and Patay, Z. (2011). Metabolic toxic and inflammatory brain disorders, in “Pediatric Neuroimmages”, V Edition Edition, (Lippincott Williams and Wilkins).

78.

Sato S, Nakajima J, Shimura M, Kawashima H, Yoshio T, Hara Y. Reversible basal ganglia lesions in neuropsychiatric lupus: a report of three pediatric cases. Int J Rheum Dis. 2014;17:274–9.PubMedCrossRef

79.

Bricout M, Grevent D, Lebre AS, Rio M, Desguerre I, De Lonlay P, et al. Brain imaging in mitochondrial respiratory chain deficiency: combination of brain MRI features as a useful tool for genotype/phenotype correlations. J Med Genet. 2014;51:429–35.PubMedCrossRef

80.

Miyamura Y, Suzuki T, Kono M, Inagaki K, Ito S, Suzuki N, et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am J Hum Genet. 2003;73:693–9.PubMedPubMedCentralCrossRef

81.

Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szynkiewicz M, et al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet. 2012;44:1243–8.PubMedPubMedCentralCrossRef

82.

La Piana R, Uggetti C, Olivieri I, Tonduti D, Balottin U, Fazzi E, et al. Bilateral striatal necrosis in two subjects with Aicardi-Goutieres syndrome due to mutations in ADAR1 (AGS6). Am J Med Genet A. 2014;164A:815–9.PubMedCrossRef

83.

Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238:91–8.PubMedCrossRef

84.

Hoffmann C, Ben-Zeev B, Anikster Y, Nissenkorn A, Brand N, Kuint J, et al. Magnetic resonance imaging and magnetic resonance spectroscopy in isolated sulfite oxidase deficiency. J Child Neurol. 2007;22:1214–21.PubMedCrossRef

85.

Bayram E, Topcu Y, Karakaya P, Yis U, Cakmakci H, Ichida K, et al. Molybdenum cofactor deficiency: review of 12 cases (MoCD and review). Eur J Paediatr Neurol. 2013;17:1–6.PubMedCrossRef

86.

Tan WH, Eichler FS, Hoda S, Lee MS, Baris H, Hanley CA, et al. Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature. Pediatrics. 2005;116:757–66.PubMedCrossRef

87.

Rocha S, Ferreira AC, Dias AI, Vieira JP, Sequeira S. Sulfite oxidase deficiency—an unusual late and mild presentation. Brain Dev. 2014;36:176–9.PubMedCrossRef

88.

Hughes EF, Fairbanks L, Simmonds HA, Robinson RO. Molybdenum cofactor deficiency-phenotypic variability in a family with a late-onset variant. Dev Med Child Neurol. 1998;40:57–61.PubMedCrossRef

89.

Alkufri F, Harrower T, Rahman Y, Hughes E, Mundy H, Knibb JA, et al. Molybdenum cofactor deficiency presenting with a parkinsonism-dystonia syndrome. Mov Disord. 2013;28:399–401.PubMedCrossRef

90.

Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE, Messing A. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet. 2001;27:117–20.PubMedCrossRef

91.

Prust M, Wang J, Morizono H, Messing A, Brenner M, Gordon E, et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology. 2011;77:1287–94.PubMedPubMedCentralCrossRef

92.

Farina L, Pareyson D, Minati L, Ceccherini I, Chiapparini L, Romano S, et al. Can MR imaging diagnose adult-onset Alexander disease? AJNR Am J Neuroradiol. 2008;29:1190–6.PubMedCrossRef

93.

Graff-Radford J, Schwartz K, Gavrilova RH, Lachance DH, Kumar N. Neuroimaging and clinical features in type II (late-onset) Alexander disease. Neurology. 2014;82:49–56.PubMedPubMedCentralCrossRef

94.

Messing A, Li R, Naidu S, Taylor JP, Silverman L, Flint D, et al. Archetypal and new families with Alexander disease and novel mutations in GFAP. Arch Neurol. 2012;69:208–14.PubMedPubMedCentralCrossRef

95.

Mignot C, Boespflug-Tanguy O, Gelot A, Dautigny A, Pham-Dinh D, Rodriguez D. Alexander disease: putative mechanisms of an astrocytic encephalopathy. Cellular and Molecular Life Sciences (CMLS). 2004;61:369–85.CrossRef

96.

van der Knaap MS, Naidu S, Breiter SN, Blaser S, Stroink H, Springer S, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol. 2001;22:541–52.PubMed

97.

Maegawa GH, Stockley T, Tropak M, Banwell B, Blaser S, Kok F, et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics. 2006;118:e1550–1562.PubMedPubMedCentralCrossRef

98.

Nardocci N, Bertagnolio B, Rumi V, Angelini L. Progressive dystonia symptomatic of juvenile GM2 gangliosidosis. Mov Disord. 1992;7:64–7.PubMedCrossRef

99.

Fernandes Filho JA, Shapiro BE. Tay-Sachs disease. Arch Neurol. 2004;61:1466–8.PubMedCrossRef

100.

Bano S, Prasad A, Yadav SN, Chaudhary V, Garga UC. Neuroradiological findings in GM2 gangliosidosis variant B1. J Pediatr Neurosci. 2011;6:110–3.PubMedPubMedCentral

101.

Seshadri R, Christopher R, Arvinda HR. Teaching neuroimages: MRI in infantile Sandhoff disease. Neurology. 2011;77:e34.PubMedCrossRef

102.

Bomont P, Cavalier L, Blondeau F, Ben Hamida C, Belal S, Tazir M, et al. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet. 2000;26:370–4.PubMedCrossRef

103.

Bruno C, Bertini E, Federico A, Tonoli E, Lispi ML, Cassandrini D, et al. Clinical and molecular findings in patients with giant axonal neuropathy (GAN). Neurology. 2004;62:13–6.PubMedCrossRef

104.

Van der Knaap M, editor. Magnetic resonance of myelination and myelin disorders, third edition. Berlin: Springer; 2005.

105.

van der Knaap MS, Naidu S, Pouwels PJ, Bonavita S, van Coster R, Lagae L, et al. New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum. AJNR Am J Neuroradiol. 2002;23:1466–74.PubMed

106.

Simons C, Wolf NI, McNeil N, Caldovic L, Devaney JM, Takanohashi A, et al. A de novo mutation in the β-tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum. Am J Hum Genet. 2013;92:767–73.PubMedPubMedCentralCrossRef

107.

Tonduti, D., Aiello, C., Renaldo, F., Dorboz, I., Saaman, S., Rodriguez, D., Fettah, H., Elmaleh, M., Biancheri, R., Barresi, S., et al. (2015). TUBB4A-related hypomyelinating leukodystrophy: new insights from a series of 12 patients. Eur J Paediatr Neurol.

108.

Hamilton EM, Polder E, Vanderver A, Naidu S, Schiffmann R, Fisher K, et al. Hypomyelination with atrophy of the basal ganglia and cerebellum: further delineation of the phenotype and genotype-phenotype correlation. Brain. 2014;137:1921–30.PubMedPubMedCentralCrossRef

109.

Huster, D. Wilson disease. Best Pract Res Clin Gastroenterol 24, 531–539.

110.

Kim TJ, Kim IO, Kim WS, Cheon JE, Moon SG, Kwon JW, et al. MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. AJNR Am J Neuroradiol. 2006;27:1373–8.PubMed

111.

Trocello JM, Woimant F, El Balkhi S, Guichard JP, Poupon J, Chappuis P, et al. Extensive striatal, cortical, and white matter brain MRI abnormalities in Wilson disease. Neurology. 2013;81:1557.PubMedCrossRef

112.

Shoulson I, Young AB. Milestones in Huntington disease. Mov Disord. 2011;26:1127–33.PubMedCrossRef

113.

Walker RH. Untangling the thorns: advances in the neuroacanthocytosis syndromes. J Mov Disord. 2015;8:41–54.PubMedPubMedCentralCrossRef

114.

Mascalchi M, Lolli F, Della Nave R, Tessa C, Petralli R, Gavazzi C, et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology. 2004;232:867–73.PubMedCrossRef

115.

Schapiro M, Cecil KM, Doescher J, Kiefer AM, Jones BV. MR imaging and spectroscopy in juvenile Huntington disease. Pediatr Radiol. 2004;34:640–3.PubMedCrossRef

116.

Geevasinga N, Richards FH, Jones KJ, Ryan MM. Juvenile Huntington disease. J Paediatr Child Health. 2006;42:552–4.PubMedCrossRef

117.

Dusi S, Valletta L, Haack TB, Tsuchiya Y, Venco P, Pasqualato S, et al. Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am J Hum Genet. 2014;94:11–22.PubMedPubMedCentralCrossRef

118.

Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet. 2001;28:350–4.PubMedCrossRef

119.

Keogh MJ, Jonas P, Coulthard A, Chinnery PF, Burn J. Neuroferritinopathy: a new inborn error of iron metabolism. Neurogenetics. 2012;13:93–6.PubMedPubMedCentralCrossRef

120.

Lehn A, Boyle R, Brown H, Airey C, Mellick G. Neuroferritinopathy. Parkinsonism Relat Disord. 2012;18:909–15.PubMedCrossRef

121.

Mancuso M, Davidzon G, Kurlan RM, Tawil R, Bonilla E, Di Mauro S, et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol. 2005;64:280–94.PubMedCrossRef

Title: Neurological Disorders Associated with Striatal Lesions: Classification and Diagnostic Approach
Authors: Davide Tonduti
Luisa Chiapparini
Isabella Moroni
Anna Ardissone
Giovanna Zorzi
Federica Zibordi
Sergio Raspante
Celeste Panteghini
Barbara Garavaglia
Nardo Nardocci
Publication date: 01-06-2016
Publisher: Springer US
Published in: Current Neurology and Neuroscience Reports / Issue 6/2016
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-016-0656-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neurological Disorders Associated with Striatal Lesions: Classification and Diagnostic Approach

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

ALS: Recent Developments from Genetics Studies

Brain Multimodality Monitoring: Updated Perspectives

Neurologic Complications in the Intensive Care Unit

Kleine-Levin Syndrome

Progressive External Ophthalmoplegia

The Risk of Sleep Disorder Among Persons with Mild Traumatic Brain Injury